NCT07443176Not yet recruiting
FCI-Glioblastoma Study
Applying New MRI Technology to Improve Outcomes From Chemoradiotherapy Treatment for Adult Patients With Glioblastoma
Source: ClinicalTrials.gov · Last updated 30 Apr 2026
Brief summary (registry, in English)
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is: • Can FCI differentiate glioblastoma progression from pseudo-progression? Participants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 18 (estimated)
- First submitted
- 5 Feb 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Aberdeen
- Diseases
- Glioblastoma
- NCT number
- NCT07443176
What you commit to
- Study type: Observational
- Planned participants: 18
- From 1 May 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment for glioblastoma other than surgery and chemoradiation.
- Previous radiotherapy to brain and/or prior chemotherapy for lower grade glioma.
- Planned additional treatment with Tumor-Treating Fields
- Previous cytotoxic wafers or implants at the time of neurosurgery
Other illness
- Uncontrolled intercurrent illness
- Known allergy to contrast agent
Other
- Being pregnant or nursing
- Conventional MRI contraindications
- Unable to provide informed consent
Who the study is looking for
- Patients scheduled to have standard adjuvant temozolomide treatment for glioblastoma, within four weeks following radical radiotherapy with concomitant temozolomide
- 18 to 70 years old
- Life expectancy at least 12 weeks
- Able to undergo MRI scans lasting up to 1 hour each
- On stable or reducing dose of steroids for at least 5 days
- Able to provide informed consent
- Able to understand written and spoken English
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Aberdeen Coordinator of this site? Confirm its status | Aberdeen | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.